ABT Investment Analysis Report & Stock Research, Abbott Laboratories

Log InorSign Up

Abbott Laboratories (ABT)

ABT Stock Report

2-Year Price History

Recent Price
(7/2 4:20PM) -0.8%
$46.28
52-Week Price
$41.27 - $60.78
Market Capitalization
$71.5 Billion
Dividend Yield
3.50%
Most Recent Dividend
$1.41

Ockham's Rating

Rating specific information requires Premium Access.
Buy Now or Take the Tour.

ABT Revenue

For a long time, value investors have used the current share price relative to sales per share levels as an important valuation tool. We utilize a historical weighted average methodology that treats recent years more importantly in the calculation. When looking at ABT through this framework, we can see that our weighted average historical high and low Price to Sales per share ratios over the last 10 years are 3.69x and 2.73x respectively.

Utilizing this range we can see that ABT’s current Price to Sales per share ratio of 2.24x is significantly below its average levels historically. In fact, with a current price of $46.28, ABT is a full 31% below its average Price to Sales ratio at comparable sales levels. This is a rare occurrence and, when taken in context of the other areas of our analysis, can be a strong positive for our outlook for ABT.

ABT Cash Earnings

Looking at ABT specifically in their Cash Earnings capabilities, Ockham views ABT as significantly below their historical average multiples of Cash Earnings, as calculated by our proprietary analysis. It is incredibly important to understand that for ABT, the current level of Cash Earnings compared to its historical levels helps identify where ABT is in relation to what the investing community was willing to pay for this level of Cash Earnings in the past. With a historical high Cash Earnings per share ratio of 18.34 and a historical low Cash Earnings per share ratio of 13.64, an investor can relate where value becomes optimal.

So what does "significantly below" mean when we talk about Price to Cash Earnings numbers for ABT? From the Ockham perspective, we are looking specifically at ABT to see if the market is recognizing the huge disparity between ABT's past stock price to Cash Earnings ratio to today's levels. At a difference of 39% below the average historical Price to Cash Earnings ratio, our view would be quite positive at this point. However, as with all metrics, we need to also take other factors into account when looking at ABT. While we view better Cash Earnings metrics as very important, if the market is slow to identify this value, or if Cash Earnings were to fall from these levels, we would become more neutral in our stance.

ABT Dividends

A positive Ockham rating does not require a company to pay out an inviting dividend or a dividend at all. However, we believe dividends provide a useful measure of a company's inherent expectations.

Comparable to our analysis of Sales and Cash Earnings per share, we examine dividend yields from ABT against the historic high and low levels over an available data range. Because ABT has an established history of paying a dividend to shareholders, there is value in comparing recent dividends to historical dividends. In ABT’s case, the estimated annual dividend is $1.60 producing a current dividend yield of 3.46%. The highest dividend yield from ABT in recent history was 3.88% while the lowest dividend yield was 1.32%. It's hard not to notice that ABT pays a current dividend yield that is 33.08% above the historical median. This peaks our interest since our analysis is looks favorably upon dividend yields that are greater than the historical median.

Peer Comparison

:

Abbott Laboratories Industry Grouping

(7/2/2009)
Company Ticker Market Cap (Ml) Latest
Price
Price/Cash Earnings Price/Sales 5-Yr. Rev.
Growth Rate
5-Yr.
Avg. ROE.
Current 10-Yr. Range* Current 10-Yr. Range*
Peer Company Averages (not incuding ABT) 7.83 5.94 » 25.30 2.12 1.71 » 6.13 12.42% 22.70%
*10 year range does not include current year values
Novartis AG ADS NVS $90.9 Billion $40.12 8.36 7.84 » 24.82 2.07 2.27 » 6.18 10.77% 18.76%
Sanofi-Aventis ADS SNY $78.1 Billion $29.70 5.16 4.40 » 21.42 1.73 1.57 » 6.14 31.68% 6.98%
Abbott Laboratories ABT $71.5 Billion $46.28 9.89 10.59 » 32.64 2.24 2.41 » 6.33 8.45% 21.28%
AstraZeneca PLC AZN $62.6 Billion $43.21 7.18 5.44 » 22.00 1.97 1.50 » 5.96 10.89% 34.96%
Wyeth WYE $59.8 Billion $44.81 11.01 6.91 » 32.14 2.56 1.64 » 6.45 7.57% 23.98%
Merck & Company, Inc. MRK $57.0 Billion $27.01 7.44 5.12 » 26.11 2.29 1.58 » 5.93 1.19% 28.84%
>
Ockham Ratings & Analysis Report
powered by Psydex

The latest TV Media Discussion

10:19:04 AM ABT $43.75 Abbott Laboratories
RAZORWIRE
Fox Business
4/17/2009 10:19 AM
“…Global industries, that blue chips, that run down as much as the rest of the market and great quality companies, trading at the same price as crummy companies, and an example would be abbott labs, abt, a medical products company that has diagnostics, medical devices, and stents, a bestseller, bioengineered product, humera, …” …more details…
5:12:12 PM ABT $47.89 Abbott Laboratories
RAZORWIRE
Fast Money
3/30/2009 5:12 PM
“…But abbott, what did did today. Their major drugs don't come off of patent until 2017. Lipitor and pfizer comes off abbott sets up nicely on value yags on a lot of different I still like abt. >> and petey, on those potential targets that you named, do you like buying outside calls on some of those targets as a gamble >> you do? >> activity all of the time, and one name that gets interesting. …” …more details…
7:33:48 PM ABT $54.46 Abbott Laboratories
RAZORWIRE
America's Nightly Scoreboard
2/19/2009 7:33 PM
“…Two of the premiere business people in california coming up live here on "scoreboard". And we want to know what you indid on madoff or what they didn't do on madoff. Didn't do on madoff. Abt on stanford? Sell or a text your message to 369249. …” …more details…
2:40:24 PM ABT $54.32 Abbott Laboratories
RAZORWIRE
Street Signs
2/18/2009 2:40 PM
“…40% in 2008, the medallion fund and on average 30% per year since inception. >> which stocks is medallion >> one of their largest new positions is ABBOTT LABORATORIES, abt, the company trades for 13 times forward earnings, and in terms of safety, this company raises dividends every year for 25 years in a row. I think it's a great plan and …” …more details…
3:28:25 PM ABT $54.39 Abbott Laboratories
RAZORWIRE
Closing Bell
1/27/2009 3:28 PM
“…Has been in the witness protection program for a number he has put a lot of guys away in jail. He helped convict nicholas gaginiani a couple years ago. He's a major inform abt and what he is telling federal authorities, nick cosmo, he and another associate was one of the guys who attempted to collect money on behalf of the genovese, …” …more details…
View All Abbott Laboratories News

Key Fundamentals

ABT - Abbott Laboratories Fundamentals
Price (7/2 4:20PM) $46.28
Volume (7/2 4:20PM) 7.6 Million
Last Close Price $46.64
10 Day Average Volume 8.6 Million
13 Week Price Range $41.27 - $48.37
52 Week Price Range $41.27 - $60.78
LTM Revenue $29.5 Billion
 
Shares Outstanding (12/2008) 1.5 Billion
Market Capitalization $71.5 Billion
Shares Held By Institutions 1.1 Billion
Institutional Holders 1,682
% Shares Held By Institutions 69.70%
Earnings Per Share (EPS) $3.12
P/E Ratio 13.50
Book Value Per Share $11.61
 
Gross Margin 63.60%
Annual Dividend 1.60
Dividend Yield 3.50%
Beta 0.21
Fiscal Year Ends December

About Abbott Laboratories

Abbott Laboratories is considered to operate in the Healthcare sector. They specifically operate in the Drug Manufacturers/Major business segment contained within the Drugs industry.

The Company is engaged in the discovery, development, manufacture and sale of a line of health care products.

Market Direction
NASDAQ 1796.52

-49.2  -2.67%
Market Direction
S&P 500 896.42

-26.91  -2.91%
Market Direction
^DIA 82.99

-2.04  -2.4%